Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL

2.

Is Exercise an Effective Treatment for Prostate Cancer?

3.

Which Risk Model Better Identifies High-Risk Smoldering MM?

4.

Spouses of Cancer Patients May Be at Increased Risk of Suicide

5.

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot